CUMBERLAND PHARMACEUTICALS, INC.

Basic Information

CUMBERLAND PHARMACEUTICALS INC.
2525 WEST END AVE, STE 950
NASHVILLE, TN, 37203

Company Profile

n/a

Additional Details

Field Value
DUNS: 69532880
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Radioprotection by use of Topical Lithium Formulations

    Amount: $121,528.00

    DESCRIPTION (provided by applicant): Roughly 500,000 cancer patients are treated with radiotherapy each year. Acute and late sequelae of radiotherapy have a negative impact upon the quality of life of ...

    STTR Phase I 2009 Department of Health and Human Services
  2. Mannan, A Potential Therapeutic for Asthma

    Amount: $111,805.00

    DESCRIPTION (provided by applicant): The long-term goal of this application is to develop mannan derived from Baker's yeast as asthma therapy. The limitations of currently available immunomodulators a ...

    STTR Phase I 2009 Department of Health and Human Services
  3. High Purity Amphotericin B: A Safer Antimycotic in AIDS

    Amount: $110,644.00

    DESCRIPTION (provided by applicant): Cumberland Pharmaceuticals and the University of Mississippi Mycotic Research Centers' long-term goal will be to improve anti-fungal pharmacotherapy particularly ...

    STTR Phase I 2005 Department of Health and Human Services
  4. TGF-beta for Pleurodesis

    Amount: $749,143.00

    DESCRIPTION (provided by applicant): Approximately 50,000 cancer patients a year have recurrent fluid accumulation in the space between their chest wall and lung. This condition is called malignant pl ...

    STTR Phase II 2004 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government